Email us at: wbcil@wbcil.com
Chewable Iron Tablets for Iron Polymaltose Complex
Published on: November 17, 2026
Author: WBCIL Team
0 views

Iron Polymaltose Complex in Chewable Iron Tablets: API Insights

Managing iron deficiency requires more than just increasing iron intake. Patients and formulators alike struggle with iron supplements that cause nausea, metallic aftertaste, and poor tolerability. Iron polymaltose complex has changed this by offering a stable, non-ionic iron form that behaves gently in the gastrointestinal tract. Chewable iron tablets built on this API combine patient acceptability with reliable therapeutic outcomes across diverse populations.

In this blog, you will find the API specifications, clinical rationale, stability requirements, and regulatory considerations behind iron polymaltose complex in chewable iron tablets.

Key Takeaways

  • Iron polymaltose complex releases no free ionic iron during chewing, eliminating metallic taste and tooth discolouration.
  • Chewable iron tablets for adults typically deliver 100 to 300 mg elemental iron daily over three to five months.
  • API suppliers must provide WHO-GMP certification, ICH Q1A stability data, and a valid drug master file for supply to regulated markets.

Quick Answer: Iron polymaltose complex is preferred in chewable iron tablets because its non-ionic structure prevents metallic taste, tooth staining, and gastrointestinal irritation during oral breakdown.

iron polymaltose complex for chewable tablets

Why Iron Polymaltose Works in Chewable Iron Tablets

Chewable iron tablets present a formulation challenge that rules out most ionic iron salts. Ferrous sulfate and ferrous fumarate release free iron ions when crushed or chewed, producing metallic taste, tooth staining, and mucosal irritation that reduces patient compliance. Iron polymaltose complex solves this through its molecular architecture.

A polymaltose shell surrounds the ferric hydroxide core, keeping iron in a non-ionic, stable coordination state. When a chewable iron tablet breaks down in the mouth, it releases no free ionic iron. The result is a neutral taste profile, no tooth discolouration, and no mucosal contact with reactive iron species. These properties make iron polymaltose the preferred API for chewable iron supplements across regulated pharmaceutical markets.

The complex carries a molecular weight of approximately 55 kD and contains about 27% iron by mass [1]. The standard commercial strength is 100 mg elemental iron per tablet, equivalent to 357 to 400 mg of iron(III) hydroxide polymaltosate per dose depending on batch yield [2].

For WHO-GMP iron polymaltose manufacturers, this structural stability is the primary clinical and commercial rationale for choosing this API over ionic iron forms in any chewable solid oral dosage form.

Chewable Iron Tablets: Dosage and Patient Population

Chewable iron tablets containing iron polymaltose complex are indicated for iron deficiency anaemia and iron deficiency without anaemia in adults, adolescents, and paediatric patients. The dosage range for adults with documented iron deficiency anaemia is 100 to 300 mg elemental iron daily, given as one to three chewable iron tablets per day. [1]

The standard adult regimen uses two 100 mg tablets daily, taken during or immediately after a meal. This feeding-state administration is a key clinical distinction from ionic iron salts, which often must be taken on an empty stomach and therefore produce higher rates of gastrointestinal intolerance.

Adult Dosage

Adult chewable iron tablets are typically dosed at 200 mg elemental iron per day for 12 weeks, with haemoglobin response assessed at weeks 4, 8, and 12. [1] Under standard dosing conditions, the expected haemoglobin rise over this period is 8-15 g/L.

Paediatric and Prophylactic Use

For children, lower-strength chewable iron supplements deliver 50 mg elemental iron per dose. Pregnant women follow the adult range of 100 to 300 mg daily, with dose selection guided by baseline haemoglobin and ferritin values.

Stability of Chewable Iron Supplements

API Specs That Define Chewable Iron Tablet Quality

The API specification for iron polymaltose in chewable iron tablets must go beyond parameters required for standard compressed tablets. Because the dosage form undergoes direct oral breakdown, the specification must confirm that the iron-polymaltose coordination bond remains intact under mechanical stress and salivary pH conditions during chewing.

Parameter Specification Relevance to Chewable Form
Identity IR spectroscopy confirming iron-polymaltose coordination. Verifies structural integrity of the complex.
Elemental iron assay 95.0 to 105.0% of labelled claim. Ensures consistent therapeutic dose per tablet.
Iron content by mass  Approximately 27% of dried complex [1] Defines API potency benchmark
Molecular weight Around 55 kD by gel permeation chromatography [1]. Confirms polymaltose chain integrity.
Appearance Dark brown to black, uniform, contamination-free. Release criterion for visual quality.
Organoleptic Taste and odour assessed at batch release. Critical for patient acceptability in chewable iron supplements.
Tablet hardness Within range permitting oral breakdown without fragmentation. Safety and usability criterion.
Moisture content Controlled by Karl Fischer titration. Prevents polymaltose ligand hydrolysis during shelf life.
Microbial limits Per BP or USP solid oral dosage monograph. Microbiological safety at point of use.
Heavy metals Per ICH Q3D elemental impurity assessment Covers iron synthesis route contaminants

Stability Considerations for Chewable Iron Supplements

Chewable iron supplements introduce stability challenges that do not arise in conventional compressed tablets. The chewable dosage form typically incorporates sweeteners, flavouring agents, and chewable excipients such as mannitol or sorbitol that interact with the iron-polymaltose coordination environment over the product’s shelf life. API manufacturers and formulators must account for these interactions during development.

Moisture and Hygroscopicity

The iron polymaltose complex is hygroscopic. In a chewable matrix containing sorbitol or mannitol, moisture uptake is accelerated under humid storage conditions. Moisture ingress at the API level can promote hydrolysis of the polymaltose ligand, changing molecular weight distribution and the iron release profile over time. Packaging in aluminium blister or moisture-barrier laminate is standard for chewable iron tablets to control this risk.

Temperature and Light

Store chewable iron tablets below 25°C and protect them from direct light. Iron polymaltose complex is photosensitive at the product level, and the iron-carbohydrate bond is susceptible to photodegradation with extended light exposure. Dark or opaque primary packaging is therefore a formulation requirement, not a cosmetic preference.

Excipient Compatibility

Mannitol and sorbitol are compatible co-excipients at standard chewable tablet concentrations. Screen flavouring agents for compatibility with the iron complex, as acidic flavour systems can shift the microenvironment pH toward conditions that destabilise the ferric core. Use stearic acid or magnesium stearate as lubricants at minimum levels to avoid interfering with the coordination structure of chewable iron supplements.

What to Demand from an Iron Polymaltose API Supplier

Finished-dose manufacturers developing chewable iron tablets need an API supplier that can support both the product’s technical and regulatory requirements. A WHO-GMP iron polymaltose manufacturer supplying this dosage form must provide documentation that covers chemical characterisation, process consistency, and market-specific regulatory filings.

Technical Package

A WHO-GMP iron polymaltose manufacturer must supply the following for each production batch and as part of the drug master file:

  • Certificate of analysis covering identity, assay, elemental iron content, molecular weight distribution, water content, microbial limits, and heavy metals per ICH Q3D.
  • ICH Q1A-compliant stability data at 25°C/60% RH and 40°C/75% RH, covering real-time and accelerated conditions for the full proposed shelf life.
  • Synthesis route documentation covering the iron source, polymaltose preparation, and complexation process with defined in-process controls.
  • Genotoxic impurity risk assessment per ICH M7 for all reagents and intermediates in the polymaltose synthesis step.
    Particle size distribution data where the API is used in direct compression or roller compaction for chewable tablet manufacture.

Regulatory Standing

A WHO-GMP iron polymaltose manufacturer supplying chewable iron tablets for export markets must hold current WHO-GMP certification as a minimum. Supplying the EU market requires an ASMF or CEP from EDQM. US NDA and ANDA products require a valid Type II DMF filed with the FDA. Finished-dose manufacturers should reconfirm API site regulatory standing at each procurement cycle rather than relying solely on documentation from the initial qualification audit.

Final Thoughts

Chewable iron tablets occupy a critical niche where patient tolerability and clinical efficacy must align without compromise. The API specification for iron polymaltose complex in chewable iron tablets determines how well that balance holds across batches, markets, and patient groups. Formulators entering this segment should prioritise suppliers who provide full ICH Q1A stability data, ICH M7 genotoxic impurity assessments, and market-specific drug master file filings from the outset.

Verifying API site regulatory standing at every procurement cycle, not just at initial qualification, is a practical step that significantly reduces downstream supply risk. Manufacturers that source from a WHO-GMP- and cGMP-certified facility with dedicated iron polymaltose expertise, such as WBCIL, are better positioned to meet both the technical rigour and regulatory continuity that global buyers now expect.

Updated on: November 17, 2026
WBCIL Team
WBCIL Team
As the WBCIL team, we take pride in creating helpful, science-based guides for the pharmaceutical, nutraceutical, cosmeceutical, and other industries. We believe in safety and reliability, which is why we are always looking for better ways to research and provide you with accurate and engaging information. For us, it’s about more than just blogs—it’s about a commitment to excellence and helping people live healthier lives everywhere.
References
  1. Toblli JE, Brignoli R. Iron(III)-hydroxide polymaltose complex in iron deficiency anaemia. Arzneimittelforschung. 2007;57(6):431-438. https://doi.org/10.1055/s-0031-1296692
  2. NCT03993288 Clinical Study Protocol. ClinicalTrials.gov. https://cdn.clinicaltrials.gov/large-docs/88/NCT03993288/Prot_000.pdf
Frequently Asked Questions on: Iron Polymaltose Complex in Chewable Iron Tablets: API Insights
Are chewable iron tablets as effective as iron syrup for treating anaemia?

Yes. Chewable iron tablets and iron syrup containing iron polymaltose complex deliver equivalent elemental iron doses and show comparable haemoglobin response rates over a 12-week treatment course.

Can chewable iron supplements cause tooth staining?

No. Iron polymaltose complex releases no free ionic iron during chewing, which means the staining risk associated with ferrous sulfate and ferrous fumarate tablets does not apply.

Should chewable iron tablets be taken with food or on an empty stomach?

Take chewable iron tablets containing iron polymaltose complex during or immediately after a meal. This distinguishes them from ionic iron salts, which require fasting administration to maximise absorption.

How long does it take for chewable iron tablets to raise haemoglobin levels?

Clinical data shows an expected haemoglobin rise of 8 to 15 g/L over 12 weeks of standard dosing at 200 mg elemental iron per day in adults with iron deficiency anaemia.

What is the difference between iron polymaltose and ferrous sulfate in chewable tablets?

Iron polymaltose complex is non-ionic and stable in the mouth, producing no metallic taste or mucosal irritation. Ferrous sulfate releases free iron ions on breakdown, causing taste aversion, staining, and gastrointestinal discomfort that reduces patient compliance.


Related Products
Close Language
Product List Request Sample
Write a Mail WBCIL WhatsApp WhatsApp